The Charcot-Marie-Tooth Association proudly celebrates Professor Mary M. Reilly, MD, CMTA-STAR Clinical Expert Board Co-Chair, on being awarded the prestigious Honorary Member of the Order of the British Empire (MBE) in recognition of her outstanding contributions to neurology and neuromuscular disease research.
The MBE honor is awarded by His Majesty The King to individuals who have made an outstanding contribution to the United Kingdom, highlighting Prof. Reilly’s impact in advancing inherited neuropathy science and clinical care.
A world leader in inherited neuropathies, Prof. Reilly has spent decades advancing the understanding, diagnosis, and treatment of Charcot-Marie-Tooth disease (CMT). As Co-Chair of CMTA-STAR’s Clinical Expert Board (CEB), she has played a vital role in shaping research strategies, accelerating therapeutic development, and improving clinical care for people with CMT worldwide.
Beyond her research and clinical work, Prof. Reilly has led the development of key institutions dedicated to advancing neuromuscular disease research. She co-founded the University College London (UCL) Queen Square Clinical Trials Centre, a central hub for collaborative research in neurology and neurosurgery. She co-directs the UCL Centre for Neuromuscular Disease, a leading center focused on improving patient care and treatment options. She is Co-Director of the UCL International Centre for Genomic Medicine in Neuromuscular Diseases, helping drive international collaborations to accelerate genetic discoveries and therapeutic innovations for inherited neuropathies. Prof. Reilly is also the CMTA Center of Excellence at UCL Clinic Director.
Prof. Reilly’s leadership extends into clinical trials, including her ongoing Hereditary Sensory Neuropathy Serine (SENSE) trial, a CMTA-supported study investigating L-serine as a potential treatment for Hereditary Sensory Neuropathy Type 1 (HSN1) now in Phase II.
In addition to her role with CMTA-STAR, Prof. Reilly is a key investigator with the Inherited Neuropathy Consortium (INC), a global network dedicated to advancing CMT research. Through CMTA’s new strategic alliance with INC, her work continues to shape the future of CMT research, strengthening collaborative efforts to bring meaningful progress to the CMT community.
CMTA extends its deepest congratulations to Prof. Reilly on this well-deserved honor. Her groundbreaking contributions to CMT research and clinical care continue transforming the landscape for those living with CMT. We are grateful for her leadership, expertise, and unwavering commitment to improving the lives of individuals with CMT. We look forward to the continued impact of her work.
Published on: February 18, 2025